Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.

Living with Cancer Resources and Support – February 2022

Pathogenesis And Clinical Practice In Gastroenterology, 46% OFF

Sarah Maciet (Leadbetter) on LinkedIn: #progresshappenstogether #cancer # oncology #liquidbiopsy

Join NYOH at Free Lung Cancer Event on Saturday, October 10th at 2pm

Cancer Research News American Cancer Society

Radiation Oncology CME/CE Continuing Medical Education Courses

Systematic Review Of The Management Of Brain Metastases, 50% OFF

Creative Options, ADT Program, Creative Options

Recent Developments In Endometrial Cancer Research, 42% OFF

Current Oncology, Free Full-Text

Oncology Nursing (@oncologynursing) • Instagram photos and videos

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

PDF) Publisher's Note: Continued Publication of Current Oncology

Oncology Times on X: #UpToDate® and #Oncology Times are